Form 4 for SMMT Summit Therapeutics Inc.
Accepted 2024-09-13 00:00:00 ET · period of report 2024-09-11 · accession 0001599298-24-000141 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-09-13 | 2024-09-11 | SMMT | Zanganeh Mahkam | Co-CEO, Dir | A - Grant | $22.70 | +44.1K | 24.97M | +0.2% | +$1000.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-11 | A | A | 44,052 | $22.70 | 24,967,852 | I By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee | — | — | (F1) Acquired in a private placement transaction pursuant to the terms of a definitive agreement, dated as of September 11, 2024, pursuant to which the Issuer agreed to sell shares of common stock to the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee, at a purchase price of $22.70 per share. The transaction closed on September 13, 2024. (F2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |